15 Papers
176 Citations
Tom Verhaeghe is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Cmax & Galantamine. The author has an hindex of 10, co-authored 15 publications.
Chat about Author
Papers
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Steven J. Cohen,Linus Ho,Sulabha Ranganathan,James L. Abbruzzese,R. Katherine Alpaugh,Mary Beard,Nancy L. Lewis,Susan McLaughlin,Andre Rogatko,Juan J. Perez-Ruixo,Amanda M. Thistle,Tom Verhaeghe,Hao Wang,L. M. Weiner,John J. Wright,Gary R. Hudes,N. J. Meropol +16 more
TL;DR: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer.
175
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.
Alex Hemeryck,Rita Geerts,Johan Monbaliu,Stephan Hassler,Tom Verhaeghe,Luc Diels,Willy L. M. Verluyten,Ludy van Beijsterveldt,Rao N. V. S. Mamidi,Cor G. M. Janssen,Roland De Coster +10 more
TL;DR: No undue tissue accumulation of TR and of bortezomib was observed in rats following a full clinical dosing cycle of bortsomib, and TR consisted almost exclusively of the parent drug.
55
Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
TL;DR: GAL‐ER was safe and well tolerated with or without food and was comparable to the GAL‐IR formulation in this study, and bioequivalence was demonstrated within the range of 80-125.
29
Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers
TL;DR: It appears that it would not be necessary to adjust doses of galantamine during administration to subjects with mild hepatic impairment, and in subjects with moderately impaired hepatic function, dose titration should proceed cautiously.
29
Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.
TL;DR: No dose adjustment for either risperidone or galantamine is necessary when these two drugs are administered together in the dose range evaluated, and neither of these drugs are safe and well tolerated administered either alone or together.
27